Company intelligence / Profile preview
Acadia Pharmaceuticals
San Diego, California, United Statesacadia.com ↗
- Ownership
- Public · ACAD
- Employees
- ~611
- Development stage
- Commercial
01
Overview
Acadia Pharmaceuticals has commercialized two FDA-approved drugs—Nuplazid® (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis, and Daybue™ (trofinetide) for Rett syndrome. The company continues to advance multiple clinical programs targeting central nervous system disorders including schizophrenia, major depressive disorder, Alzheimer’s disease psychosis, Prader-Willi syndrome, and rare genetic neurodevelopmental diseases. Recent clinical results include positive data in pivotal trials for their lead assets.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (e.g., pimavanserin)Peptides (e.g., trofinetide)RNA-based therapeutics (via collaboration with Stoke Therapeutics)
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
Request access →03
Partnerships
Biovail (historic partnership on pimavanserin; now ended)Stoke Therapeutics (collaboration on RNA-based therapies for rare genetic neurodevelopmental diseases)Saniona (license agreement to develop SAN711 for essential tremor)
04
Financials
- Market cap
- $4.7B
- Total revenue
- $308M
- Enterprise value
- $3.9B
Beyond the preview
Go deeper on Acadia Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acadia Pharmaceuticals.